American drug pharmaceutical firm Mylan announced the launch of its breast cancer drug through its Indian subsidiary in the country.
The drug is the world's first trastuzumab biosimilar and will be marketed under the brand name Hertraz Herceptin.
The drug, approved by the Drug Controller General of India, will available in two strengths, 440mg and 150mg, and will be used in treating patients suffering from HER2- positive metastatic breast cancer.
"Mylan is excited to offer Hertraz to the thousands of women in India suffering from metastatic breast cancer who are in need of a high quality, more affordable treatment option. The launch of Hertraz not only represents a significant milestone in our biosimilars development program with Biocon, but more importantly, supports our mission to expand access to high quality medicine around the world and demonstrates our progress against one of Mylan's key future growth drivers", Mylan CEO Heather Bresch said.